1.87BMarket Cap-3855P/E (TTM)
6.580High6.335Low3.63MVolume6.360Open6.320Pre Close23.39MTurnover1.41%Turnover RatioLossP/E (Static)291.53MShares15.74052wk High3.19P/B1.65BFloat Cap5.03552wk Low--Dividend TTM257.07MShs Float42.810Historical High--Div YieldTTM3.88%Amplitude4.540Historical Low6.442Avg Price1Lot Size
Recursion Pharmaceuticals Stock Forum
This company has so much potential. look into it before asking me why. Google
🟢 Recently Announced:
⇒ $Organon & Co (OGN.US)$ to acquire Dermavant
⇒ $Rafael Holdings (RFL.US)$ to acquire Cyclo Tx
⇒Crown Lab to acquire $Revance Therapeutics (RVNC.US)$
⇒ $Recursion Pharmaceuticals (RXRX.US)$ merger with Exscientia
🔴 Recently Closed:
⇒ $Johnson & Johnson (JNJ.US)$ acquired V-Wave
⇒ Pharmacosmos acquired $GTHX
What companies will be next? 🤔
soon all bioinformatics stocks will be in double digit
Google Deepmind founder shares Nobel prize in chemistry for AI that unlocks the shape of proteins
Ghisallo Capital Management LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
• First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
• Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient po...
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
She makes millionaires out of her clients, they all started as multimillionaires.
No comment yet